天坛生物 - Financials

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
+Revenue	6.0B	5.2B	4.3B	4.1B	3.4B
Revenue Growth %	16.4%	21.6%	3.6%	19.3%	--
Total Revenue	6.0B	5.2B	4.3B	4.1B	3.4B
Cost Of Revenue	2.7B	2.6B	2.2B	2.2B	1.7B
+Gross Profit	3.3B	2.6B	2.1B	2.0B	1.7B
Gross Margin %	54.7%	50.8%	49.1%	47.5%	49.4%
Total Operating Cost	3.6B	3.4B	2.9B	2.9B	2.4B
Selling Expenses	133.0M	271.0M	262.0M	271.0M	240.0M
Admin Expenses	481.0M	469.0M	366.0M	329.0M	257.0M
Rd Expenses	143.0M	140.0M	122.0M	133.0M	120.0M
Finance Expenses	-32.9M	-49.5M	-58.0M	-64.1M	-30.3M
+Operating Income	2.6B	1.8B	1.4B	1.2B	1.1B
Operating Margin %	42.4%	34.8%	33.6%	30.3%	32.1%
Non Operating Income	1.2M	5.0M	2.8M	634,200	5.0M
Non Operating Expenses	11.7M	11.4M	8.6M	4.5M	4.7M
Investment Income	63.9M	37.2M	28.1M	12.0M	1.2M
Asset Disposal Income	37,500	-51,800	15.6M	511,800	-116,000
Asset Impairment Loss	53.0M	2.2M	2.3M	15.1M	916,800
Other Income	40.0M	21.3M	36.4M	9.8M	24.3M
Income Before Tax	2.5B	1.8B	1.4B	1.2B	1.1B
Income Tax	435.0M	289.0M	222.0M	172.0M	162.0M
+Net Income	2.1B	1.5B	1.2B	1.1B	943.0M
Net Margin %	35.0%	29.1%	28.3%	26.0%	27.4%
Net Income Attributable	1.5B	1.1B	881.0M	760.0M	639.0M
Minority Interest	563.0M	400.0M	324.0M	309.0M	304.0M
Eps Basic	0.78	0.56	0.53	0.47	0.51
Eps Diluted	0.78	0.56	0.53	0.47	0.51

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash And Equivalents	2.7B	4.6B	3.7B	4.3B	1.7B
Accounts Receivable	203.0M	17.9M	33.3M	9.8M	12.3M
Notes Receivable	910.0M	76.3M	983.0M	1.0B	683.0M
Notes And Accounts Receivable	1.1B	94.1M	1.0B	1.0B	696.0M
Prepayments	30.9M	35.3M	24.6M	20.3M	20.0M
Inventory	3.9B	2.8B	2.3B	2.1B	2.2B
Total Current Assets	7.7B	7.6B	7.3B	7.5B	4.7B
Long Term Equity Investment	--	--	--	--	--
Fixed Assets	--	2.8B	2.5B	966.0M	967.0M
Fixed Assets Total	3.3B	2.8B	2.5B	966.0M	970.0M
Construction In Progress	--	2.0B	1.5B	1.6B	1.0B
Construction In Progress Total	2.5B	2.0B	1.5B	1.6B	1.0B
Intangible Assets	917.0M	687.0M	442.0M	371.0M	252.0M
Long Term Deferred Expenses	117.0M	107.0M	64.4M	32.4M	32.8M
Total Non Current Assets	8.1B	6.6B	5.7B	4.0B	2.9B
Total Assets	15.9B	14.2B	12.9B	11.6B	7.5B
Short Term Borrowings	--	--	--	--	200.0M
Accounts Payable	75.9M	74.4M	69.3M	73.4M	44.9M
Advance Receipts	--	1.2M	--	--	--
Contract Liabilities	213.0M	356.0M	293.0M	215.0M	201.0M
Total Current Liabilities	1.1B	1.3B	1.2B	810.0M	939.0M
Long Term Borrowings	--	--	254.0M	366.0M	475.0M
Total Non Current Liabilities	216.0M	154.0M	416.0M	501.0M	571.0M
Total Liabilities	1.3B	1.4B	1.6B	1.3B	1.5B
Paid In Capital	2.0B	1.6B	1.6B	1.4B	1.3B
Capital Reserve	2.5B	2.8B	2.8B	3.1B	275.0M
Surplus Reserve	288.0M	262.0M	259.0M	254.0M	251.0M
Retained Earnings	6.4B	5.1B	4.1B	3.4B	2.7B
Minority Equity	3.4B	2.9B	2.6B	2.2B	1.5B
Equity Attributable	11.1B	9.8B	8.8B	8.1B	4.5B
Total Equity	14.5B	12.8B	11.4B	10.3B	6.0B

Line Item	FY 2024Dec 31, 2024	FY 2023Dec 31, 2023	FY 2022Dec 31, 2022	FY 2021Dec 31, 2021	FY 2020Dec 31, 2020
Cash From Sales	4.9B	6.3B	4.1B	3.7B	3.2B
Tax Refunds Received	--	--	37,000	94.00	71,600
Total Operating Cash Inflow	5.1B	6.4B	4.2B	3.9B	3.4B
Cash Paid For Goods	2.2B	2.0B	1.5B	1.3B	1.3B
Cash Paid To Employees	1.1B	1.1B	921.0M	876.0M	729.0M
Taxes Paid	637.0M	582.0M	413.0M	387.0M	363.0M
Total Operating Cash Outflow	4.2B	4.0B	3.1B	2.9B	2.7B
Operating Cash Flow	820.0M	2.4B	1.1B	980.0M	702.0M
Total Investing Cash Inflow	1.0B	1.5B	1.0B	8.7M	5.8M
Total Investing Cash Outflow	2.9B	2.8B	2.9B	2.2B	626.0M
Investing Cash Flow	-1.9B	-1.2B	-1.9B	-2.2B	-620.0M
Cash From Borrowings	--	--	--	--	400.0M
Dividends And Interest Paid	353.0M	122.0M	246.0M	192.0M	143.0M
Debt Repayments	--	366.0M	107.0M	326.0M	--
Total Financing Cash Inflow	--	--	1.0M	3.3B	401.0M
Total Financing Cash Outflow	370.0M	508.0M	379.0M	558.0M	147.0M
Financing Cash Flow	-370.0M	-508.0M	-378.0M	2.8B	254.0M
Net Change In Cash	-1.4B	639.0M	-1.1B	1.6B	336.0M
Ending Cash Balance	1.4B	2.8B	2.2B	3.3B	1.7B
Capex	1.1B	1.1B	1.4B	1.1B	609.0M